Erin Deegan, MD
Neurology · Cincinnati, OHNPI 1033344239
Payments from drug & device makers
Across 154 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$611
- Amneal Pharmaceuticals LLC$262
- Amgen$231
- Neurocrine Biosciences, Inc.$230
- Teva Pharmaceuticals USA, Inc.$217
- CSL Behring$145
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,72195%
- Education$1465%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 39 | $611 |
| Amneal Pharmaceuticals LLC | 21 | $262 |
| Amgen | 11 | $231 |
| Neurocrine Biosciences, Inc. | 15 | $230 |
| Teva Pharmaceuticals USA, Inc. | 7 | $217 |
| CSL Behring | 4 | $145 |
| Lundbeck LLC | 5 | $111 |
| Lilly USA, LLC | 6 | $103 |
| MDD US Operations, LLC | 6 | $79 |
| Revance Therapeutics, Inc. | 1 | $70 |
| Sanofi | 4 | $69 |
| Genentech USA, Inc. | 4 | $67 |
| Novartis | 3 | $59 |
| Merz Pharmaceuticals, LLC | 2 | $57 |
| Acadia Pharmaceuticals Inc | 3 | $56 |
| Biohaven Pharmaceuticals, Inc. | 2 | $51 |
| Adamas Pharmaceuticals, Inc. | 3 | $50 |
| SK Life Science, Inc. | 2 | $47 |
| Biogen | 2 | $41 |
| Grifols USA, LLC | 2 | $39 |
| Mallinckrodt Hospital Products Inc. | 1 | $36 |
| Medtronic | 1 | $34 |
| Boston Scientific | 1 | $28 |
| Neurelis, Inc. | 1 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| GE HealthCare | 1 | $21 |
| Argenx US, Inc. | 1 | $20 |
| Avion Pharmaceuticals | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
| Eisai Inc. | 1 | $13 |
How this compares
$2,867 in reported general payments places this provider in the 55th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 151 | $2,997 |
| Gabapentin | 89 | $838 |
| Primidone | 25 | $520 |
| Escitalopram Oxalate | 62 | $463 |
| Levetiracetam | 13 | $336 |
| Donepezil Hcl | 40 | $322 |
| Mirtazapine | 31 | $268 |
| Clonazepam | 17 | $176 |
| Amitriptyline Hcl | 17 | $174 |
| Memantine Hcl | 19 | $136 |
| Prednisone | 18 | $61 |
| Lamotrigine | 11 | $51 |
Paid to pharmacies, not to this prescriber.
Other neurology in Cincinnati
- Aram ZabetiCincinnati$5.3M
- Hani KushlafCincinnati$1.9M
- Alberto EspayCincinnati$785K
- Brandon ForemanCincinnati$677K
- Andrew DukerCincinnati$620K
- Michelle BowmanCincinnati$419K
- Joel VandersluisDayton$12.3M
- Jerry MendellColumbus$11.5M
- Lawrence GoldstickDayton$6.9M
- Douglas ScharreColumbus$6.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.